Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - VistaGen Therapeutics, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date
of Report (Date of earliest event reported): December 10, 2019
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
NEVADA
|
000-54014
|
20-5093315
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
343 Allerton Ave.
South San Francisco, California 94090
|
(Address of principal executive offices)
|
(650)
577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a -12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e
-4(c))
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common Stock, par
value $0.001 per share
|
VTGN
|
Nasdaq Capital
Market
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (17 CFR
230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17
CFR 240.12b-2)
Emerging Growth Company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act ☐
Item 8.01. Other Events.
On
December 10, 2019, VistaGen
Therapeutics, Inc. (the “Company”) announced that
the U.S. Food and Drug Administration has granted Fast Track
designation for development of PH94B, the Company's neuroactive
nasal spray, for on-demand treatment of social anxiety disorder. A
copy of the press release is attached to this Current Report on
Form 8-K as Exhibit 99.1.
Item
9.01. Exhibits.
See Exhibit
Index.
Signatures
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
VistaGen
Therapeutics, Inc.
|
|
|
|
|
Date:
December 12, 2019
|
By:
|
/s/ Shawn K. Singh
|
|
|
Shawn K.
Singh
Chief Executive
Officer
|
EXHIBIT INDEX
Exhibit Number
|
|
Description
|
|
|
|
|
Press
Release issued by VistaGen Therapeutics, Inc., dated December 10,
2019.
|